NATIONAL INSTITUTES OF HEALTH

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary, Private

Established: 1948-01-01

Employees: 1K

Market Cap: -

Website: http://www.nidcr.nih.gov

Clinical Trials

Biospecimen Collection in Identifying Genetic Changes in Patients With Breast, Prostate, Colorectal, Liver, or Kidney Cancer or Multiple Myeloma Undergoing Surgery

Suspended

Conditions: Invasive Carcinoma
Liver Carcinoma
Malignant Solid Neoplasm
Kidney Carcinoma
Colon Carcinoma
Multiple Myeloma
Prostate Carcinoma
Breast Carcinoma

Interventions: Procedure: Biospecimen Collection
Other: Laboratory Biomarker Analysis

First Posted Date: 2021-07-09

Last Posted Date: 2025-02-27

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 2400

Registration Number: NCT04955808

Locations: 🇺🇸
National Cancer Institute Division of Cancer Prevention, Rockville, Maryland, United States

Abemaciclib in Patients With HIV-associated and HIV-negative Kaposi Sarcoma

Phase 1

Recruiting

Conditions: Kaposi Sarcoma

Interventions: Drug: Abemaciclib

First Posted Date: 2021-06-28

Last Posted Date: 2025-03-13

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 86

Registration Number: NCT04941274

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Testing A New Combination of Anti-cancer Immune Therapies, Atezolizumab and CDX-1127 (Varlilumab) With or Without the Addition of a Third Anti-cancer Drug, Cobimetinib, for Advanced-Stage Biliary Tract Cancer

Phase 2

Active, not recruiting

Conditions: Metastatic Distal Bile Duct Adenocarcinoma
Unresectable Liver Carcinoma
Metastatic Gallbladder Carcinoma
Recurrent Distal Bile Duct Adenocarcinoma
Metastatic Intrahepatic Cholangiocarcinoma
Recurrent Gallbladder Carcinoma
Recurrent Intrahepatic Cholangiocarcinoma
Stage IV Distal Bile Duct Cancer AJCC v8
Stage IV Gallbladder Cancer AJCC v8
Stage IV Intrahepatic Cholangiocarcinoma AJCC v8

Interventions: Biological: Atezolizumab
Procedure: Biopsy
Procedure: Biospecimen Collection
Drug: Cobimetinib
Procedure: Computed Tomography
Procedure: Magnetic Resonance Imaging
Drug: Varlilumab

First Posted Date: 2021-06-28

Last Posted Date: 2025-05-23

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 57

Registration Number: NCT04941287

Locations: 🇺🇸
UM Sylvester Comprehensive Cancer Center at Aventura, Aventura, Florida, United States
🇺🇸
Emory Saint Joseph's Hospital, Atlanta, Georgia, United States
🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

and more 26 locations

Obeticholic Acid for Prevention in Barrett's Esophagus

Phase 2

Recruiting

Conditions: Barrett Esophagus
Esophageal Adenocarcinoma

Interventions: Procedure: Biospecimen Collection
Procedure: Esophageal Biopsy
Procedure: Esophagogastroduodenoscopy
Procedure: Liver Ultrasonographic Elastography
Drug: Placebo Administration
Biological: Obeticholic Acid
Other: Questionnaire Administration

First Posted Date: 2021-06-25

Last Posted Date: 2025-05-04

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 30

Registration Number: NCT04939051

Locations: 🇺🇸
Case Western Reserve University, Cleveland, Ohio, United States
🇺🇸
University of Kansas Cancer Center, Kansas City, Kansas, United States
🇺🇸
University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States

and more 5 locations

Immunotherapy With or Without Radiation Therapy for Metastatic Urothelial Cancer

Phase 2

Terminated

Conditions: Metastatic Urothelial Carcinoma
Platinum-Resistant Urothelial Carcinoma
Stage IV Bladder Cancer AJCC v8

Interventions: Procedure: Biospecimen Collection
Procedure: Bone Scan
Procedure: Computed Tomography
Procedure: Magnetic Resonance Imaging
Biological: Pembrolizumab
Procedure: Positron Emission Tomography
Other: Questionnaire Administration
Radiation: Stereotactic Body Radiation Therapy

First Posted Date: 2021-06-23

Last Posted Date: 2025-01-29

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 1

Registration Number: NCT04936230

Locations: 🇺🇸
Springfield Memorial Hospital, Springfield, Illinois, United States
🇺🇸
Marshfield Medical Center - Minocqua, Minocqua, Wisconsin, United States
🇺🇸
Littleton Adventist Hospital, Littleton, Colorado, United States

and more 80 locations

Copanlisib With Dose-Adjusted EPOCH-R in Relapsed and Refractory Burkitt Lymphoma and Other High-Grade B-cell Lymphomas

Phase 1

Terminated

Conditions: High-grade B-cell Lymphoma
T-cell/Histocyte-rich Large B-cell Lymphoma
Diffuse Large B-Cell Lymphoma (DLBCL)
Germinal Center B-cell Type (GCB)
Burkitt Lymphoma

Interventions: Biological: Rituximab
Drug: Etoposide
Biological: Copanlisib
Drug: Cyclophosphamide
Drug: Doxorubicin
Drug: Vincristine
Drug: Prednisone
Diagnostic Test: ECHO
Diagnostic Test: EKG
Diagnostic Test: MRI Brain
Diagnostic Test: 18F-FDG - PET
Diagnostic Test: CT Scan
Procedure: Bone Marrow Aspiration
Procedure: Bone Marrow Biopsy
Diagnostic Test: Lumbar Puncture (LP)

First Posted Date: 2021-06-22

Last Posted Date: 2024-07-09

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 8

Registration Number: NCT04933617

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Subcutaneous Daratumumab, Once Weekly Carfilzomib, and Dexamethasone (DKd) in Patients With High-Risk Smoldering Multiple Myeloma

Phase 2

Active, not recruiting

Conditions: Multiple Myeloma

Interventions: Drug: Dexamethasone
Drug: Carfilzomib
Biological: Daratumumab

First Posted Date: 2021-06-21

Last Posted Date: 2025-05-04

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 14

Registration Number: NCT04933539

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer

Phase 2

Recruiting

Conditions: AIDS-Related Anal Carcinoma
Anal Margin Squamous Cell Carcinoma
Anal Non-Keratinizing Squamous Cell Carcinoma
Anal Squamous Cell Carcinoma
HIV Infection
Rectal Squamous Cell Carcinoma
Stage II Rectal Cancer AJCC v8
Stage IIB Anal Cancer AJCC v8
Stage III Anal Cancer AJCC v8
Stage III Rectal Cancer AJCC v8

Interventions: Procedure: Anoscopy
Procedure: Biospecimen Collection
Procedure: Colonoscopy
Drug: Capecitabine
Procedure: Computed Tomography
Procedure: Digital Rectal Examination
Procedure: Echocardiography Test
Biological: Nivolumab
Procedure: Proctoscopy
Other: Fludeoxyglucose F-18
Other: Questionnaire Administration
Drug: Fluorouracil
Procedure: Sigmoidoscopy
Radiation: Intensity-Modulated Radiation Therapy
Procedure: Lymph Node Biopsy
Procedure: Magnetic Resonance Imaging
Drug: Mitomycin
Procedure: Positron Emission Tomography

First Posted Date: 2021-06-18

Last Posted Date: 2025-05-01

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 40

Registration Number: NCT04929028

Locations: 🇺🇸
Zuckerberg San Francisco General Hospital, San Francisco, California, United States
🇺🇸
George Washington University Medical Center, Washington, District of Columbia, United States
🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States

and more 10 locations

Testing the Addition of Radiation Therapy to the Usual Treatment (Immunotherapy With or Without Chemotherapy) for Advanced Stage Non-small Cell Lung Cancer Patients Who Are PD-L1 Negative

Phase 2

Recruiting

Conditions: Lung Adenocarcinoma
Stage IIIC Lung Cancer AJCC v8
Stage IV Lung Cancer AJCC v8
Lung Adenosquamous Carcinoma
Lung Non-Small Cell Carcinoma
Stage IIIB Lung Cancer AJCC v8

Interventions: Procedure: Biopsy Procedure
Procedure: Biospecimen Collection
Procedure: Computed Tomography
Procedure: Echocardiography Test
Biological: Ipilimumab
Procedure: Magnetic Resonance Imaging
Biological: Nivolumab
Procedure: Positron Emission Tomography
Other: Quality-of-Life Assessment
Radiation: Radiation Therapy

First Posted Date: 2021-06-18

Last Posted Date: 2025-05-23

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 427

Registration Number: NCT04929041

Locations: 🇺🇸
Mayo Clinic Hospital in Arizona, Phoenix, Arizona, United States
🇺🇸
Mayo Clinic in Rochester, Rochester, Minnesota, United States
🇺🇸
Providence Queen of The Valley, Napa, California, United States

and more 213 locations

The Role of 68-Gallium-DOTATATE-PET/CT in the Imaging of Metastatic Thyroid Cancer

Phase 2

Recruiting

Conditions: Metastic Thyroid Cancer

Interventions: Drug: 68-Gallium-DOTATATE-PET/CT

First Posted Date: 2021-06-16

Last Posted Date: 2025-05-21

Lead Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Target Recruit Count: 54

Registration Number: NCT04927416

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Home Terms & Conditions Privacy Policy